The following content was first published by "Vcbeat.top", and this article is reproduced from the WeChat public account of "Proxima Ventures":
At the end of December, in Beijing, the Vcbeat.top interviewed Zhao Bo, Chairman and Founder of Biosis Healing, on topics such as the entrepreneurship history of Biosis Healing, platform technology research and development innovation, breaking foreign monopoly, product internationalization, and future development direction.
Zhao Bo, Chairman and Founder of Biosis Healing
Regarding the past and future of the company, Zhao Bo has a clear idea: "I am a doctor, and I feel more deeply and sensitively about the pain points of clinical medical care than other entrepreneurs. My company is rooted in the clinic and serves the clinic. In the future, I have a plan, and Biosis Healing will be a comprehensive solution provider for surgery."
From doctor to entrepreneur, because there are more important things to do
"I like the profession of a doctor very much, and I also enjoy the joy of a patient's recovery. I chose to start a business because there are more important things that I need to do than being a doctor." Talking about the establishment of Biosis Healing in 2012, Zhao Bo's tone is full of firmness for the original choice.
The SIS biomaterial platform, one of the main technology platforms of Biosis Healing, has a fully mature process and product pipeline, but at that time, it was still blank in China.
Zhao Bo clearly remembers that in 2005, at an annual meeting of the Hernia and Abdominal Surgery Group of the Chinese Medical Association, the chairman of the American Society of Colorectal and Anal Surgery was invited to conduct academic exchanges. In his lecture, he showed a new type of biomaterial for the treatment of anal fistulas, a very intractable minor disease.
This material is SIS material, which is derived from the submucosa of the small intestine of animals. After implantation, it can be completely degraded and absorbed, and it is resistant to infection and anti-adhesion. The material is a kind of platform material, which can be applied to the repair of almost all soft tissues in the whole body. It is the most ideal repair material at that time and even now. It has been maturely applied in the United States, but it is unknown in China.
A series of problems followed one after another. Facing technical difficulties, Zhao Bo and his start-up team came up with the spirit of "Yugong moving mountains" and systematically studied the physical and chemical properties of SIS materials from scratch.
Biosis Healing SIS biomaterial products with independent intellectual property rights
After thousands of tests, Zhao Bo has broken through the material processing and mass production process problems of SIS materials such as animal-derived tissue quality control, immunogen removal process, non-crosslinking molding process, and biological activity retention process. The company has established a SIS material preparation technology platform with independent intellectual property rights.
From one person to a group of people, this is a proven team capable of fighting tough battles
In Biosis Healing, there are many employees who have worked for more than 9 years. They follow Zhao Bo's footsteps all the way. The spirit is invisible, one person influences a group of people, and then gathers more people, and finally becomes a like-minded team.
Core team of Biosis Healing
This team of Biosis Healing has been tested and can fight tough battles. It has successively undertaken 863 key projects in the field of new materials of the Ministry of Science and Technology "twelfth five-year", construction of the "Medicine Valley No. 1" public service platform of the National Development and Reform Commission, pre-clinical research on innovative varieties of Beijing Science and Technology Commission, high-precision cultivation in the Zhongguancun National Independent Innovation Demonstration Zone and other various research projects at all levels.
The R&D team of Biosis Healing brings together young backbones from various disciplines such as surgery, materials science, molecular biology, and clinical medicine. It can independently implement new product laboratory research and development, preclinical research, clinical research, registration, system certification, pilot production conversion and other comprehensive development of innovative biological materials and medical devices.
In addition, Biosis Healing also has a strong marketing team. Li Xuejun, one of the corporate partners, is the head of the marketing business. He has more than 20 years of experience in medical device sales and has promoted the process of localization of staplers.
With the efforts of Li Xuejun and his marketing team, a number of products of Biosis Healing have won the bids for centralized procurement in many provinces and cities across the country, and have entered nearly 1,000 hospitals across the country.
This powerful team of Biosis Healing also performed exceptionally well during the epidemic.
After the outbreak of the epidemic in early 2020, faced with the current shortage of domestic anti-epidemic materials. In response to the government's call, Biosis Healing transformed the existing 100,000-level production workshop into a production workshop for medical masks and protective clothing by combining its own production advantages, took the initiative to make use of its many years of experience in production and quality management of medical device, quickly set up a number of protective product lines.
After this "epidemic", Biosis Healing team has shown the strong attitude in the face of difficulties. In 2020, the cumulative sales of the company protective products at home and abroad reached nearly 1 billion yuan, contributing to Biosis Healing's strength in helping the world fight against the new crown epidemic.
From breaking monopoly to going abroad, it is necessary to provide "Chinese solutions" to the global health field
At the end of November, "People's Daily Overseas Edition" reported with the title of "Break foreign monopolies, focus on R&D and innovation, with the participation of Specialized, Fined, Peculiar and Innovative small and medium-sized enterprises- Biomedical Shooting new vitality for development". A full-page was used to report on the story for domestic biomedical enterprises of breaking foreign monopolies and providing "Chinese solutions" for global healthcare field.
This report caused quite a stir in the biomedical industry. And one of the companies mentioned in the report is Biosis Healing.
In March 2021, Biosis Healing entered the SIS biomaterial inguinal hernia biological graft and obtained the first CE certificate for animal-derived graft in China. In May, the first European order was signed, announcing that China's SIS biomaterial products officially entered the international market.
(Biosis Healing Zhao Bo performs the operation)
From 2005, when he got involved with SIS materials, to 2012, when he formally established the company to carry out research and development, and now products are exported to foreign countries. Zhao Bo said frankly that this is not only a breakthrough of Biosis Healing, but also a showcase for China's biomedical industry to the world.
Today, more and more start-ups in China have realized the advantages of SIS biomaterials and joined the R&D team. In the face of these potential competitors, Zhao Bo said: "Biosis Healing currently has a fully mature SIS material preparation process and more than 10 product pipelines reserve. In this track, we have an absolute leading advantage."
"More and more companies and capitals can pay attention to the field of SIS materials, which is very good. We fight together. This is also a very important path for the international development of China's biomedical industry. Biosis Healing first realized the export of SIS material products, can also give you a sample to follow." Zhao Bo emphasized.
In addition, Zhao Bo, a doctor of surgery, also knows that innovation and research and development should not work behind closed doors, and the coordinated development of production, education, research and medicine is the attitude that biomedical companies should have.
In just one year in 2021, Biosis Healing has cooperated with Tianjin Medical University School of Stomatology, University of California, Los Angeles (UCLA), Institute of Process Engineering, Chinese Academy of Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital Plastic Surgery Hospital and many other institutes and universities, published 6 SCI core journals with a total impact factor of 62.055 and an average single impact factor of 10.343. The research results of Biosis Healing in the field of materials science have taken the leading position in the world.
(The situation of the papers published by Biosis Healing in 2021)
From SIS material platform to multi-arm PEG material platform, to be a comprehensive solution provider for surgery
With the development of clinical surgery and the advancement of medical technology, clinical surgery has shifted from open incision treatment to minimally invasive surgery for protective treatment, and also pays more attention to the life quality of patients after recovery.
Biosis Healing, founded by Zhao Bo, is rooted in the clinic and serves the clinic, and has a deep understanding of the pain points and difficulties in the clinic.
The SIS biomaterial platform solves the problem of tissue repair and regeneration after surgery. Another important platform of Biosis Healing, the multi-arm PEG material platform, solves the problems of tissue adhesion and rapid hemostasis during surgery.
The multi-arm PEG material is currently the only biodegradable material approved by the FDA that can be used for tissue adhesion, rapid hemostasis and wound closure in the human body.
It can bond within 10s, has high viscosity, can be completely degraded in vivo, and has the functional characteristics of strong adhesive force, low toxicity and degradability, which is significantly better than the existing fibrin adhesive and cyanoacrylate adhesive.
In 2017, the multi-arm PEG material platform was officially established in Biosis Healing. At present, based on this platform, the company has deployed a series of products including absorbable endoscopic sealing medical adhesives, and has completed animal experiments, becoming the first echelon enterprise in the world to enter the platform.
Up to now, focusing on the field of clinical surgery, Biosis Healing has deployed more than 10 products on the SIS biomaterial platform, nearly 20 products on the minimally invasive surgical instrument platform, and multi-arm PEG materials under research. The huge array of surgical clinical solutions that Biosis Healing has entered is amazing.
But Zhao Bo was not satisfied: "There are still many, many things we can do and want to do around the clinic. In the future, what Biosis Healing wants to do is China's largest provider of comprehensive solutions for clinical surgery."
Proxima Ventures Partner Mr. Sun Xiaolu is very optimistic about the business model of Biosis Healing, he once said: "A startup company like Biosis Healing, which is positioned as a provider of comprehensive surgical solutions and has dozens of products on multiple platforms, is not only rare in the domestic market, but also rare in the world. The future commercial value of Biosis Healing will have a very large room for imagination."
President Xi Jinping on May 28 called for accelerated efforts in building China into a leader in science and technology and achieving sci-tech self-reliance and self-strengthening at higher levels. Xi, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, made the remarks while addressing a meeting conflating the general assemblies of the members of the Chinese Academy of Sciences and the Chinese Academy of Engineering (CAE), and the national congress of the China Association for Science and Technology (CAST). Sci-tech self-reliance and self-strengthening should always be considered a strategic support for national development, he said. Xi said scientific and technological development must target the global sci-tech frontiers, serve the main economic battlefields, strive to fulfill the significant needs of the country and benefit people's lives and health. Scientists and engineers must closely follow current trends, take the initiative, confront problems head-on, and overcome difficulties, he added.
The national biomedical technology enterprises represented by Biosis Healing are supported by governments at all levels. We always keep in mind the purpose of "benefiting people's lives and health", respond to the call of the state, and live up to the people's trust.
With the spirit of keeping pace with the times and perseverance, we shoulders the heavy responsibilities entrusted by the times, and through technological innovation, allows more people in China and the world to enjoy better and more convenient medical services at low cost.
Proxima Partner says
The following content is from Mr. Sun Xiaolu, Partner of Proximity Ventures.
After reading the growth story of , I remembered the various scenarios of making major decisions with the founding team over the years, and I felt a lot.
Here, first of all, I would like to thank the entrepreneurial team again for giving Proxima Ventures the opportunity to lead the A round of investment.
Biosis Healing is the first project after the Proxima Phase I fund filing. At that time, there was a well-known fund in the industry competing for the lead investment, saying that the start-up company was not well-known, and when choosing an investment institution, a new fund without a brand like Proxima Ventures could not be selected, but they should be selected. To everyone's surprise, the founding team rejected the well-known fund and firmly chose us. I still remember the words of the founder's rejection on WeChat, "Although we and Proxima Ventures are now small companies with no brands, but we will work hard and rely on our own hands to successfully start a business and create a brand." I am really moved by this sentence. I have kept this WeChat screenshot, and take it out from time to time to see it, to encourage ourselves, We must work hard to make the fund platform well, and we must do our best to help the invested companies to achieve greater success.
Then, I also sincerely thank our investment partners, including Dingxin Capital, Fanghe Capital, Galaxy Yuanhui and other institutions. It is because of your concerted efforts and cooperation over the years that we have joined hands to help Biosis Healing develop and achieve today's achievements. We will continue to stand side by side and walk together!
版权所有®2019BIOSISHEALING